A Randomized, Blinded, Placebo-Controlled Study to Evaluate the Saftey and Efficacy of Oral LPCN 1154A in Women With Postpartum Depression
Latest Information Update: 20 Mar 2026
At a glance
- Drugs Brexanolone (Primary)
- Indications Postnatal depression
- Focus Registrational; Therapeutic Use
- Sponsors Lipocine
Most Recent Events
- 11 Mar 2026 According to a Lipocine media release, company expects top line results are expected early in April 2026.
- 24 Feb 2026 Actual Primary Completion Date is 16 Jan 2026.
- 24 Feb 2026 Status changed from active, no longer recruiting to completed.